Great results for PectaSol-C(R) modified citrus pectin (P-MCP) presented at the American Society of Clinical Oncology (ASCO) Genitourinary Symposium – February 8, 2018

Modified Citrus Pectin Shows Significant Benefits in Biochemically Relapsed Prostate Cancer from Isaac Eliaz on Vimeo.

Abstract 20: Effect of PectaSol-C Modified Citrus Pectin Treatment on PSA Dynamics in Non-Metastatic Biochemically Relapsed Prostate Cancer Patients: Results of a Prospective Phase II Study

Daniel Keizman1, Moshe A. Frenkel1, Avivit Peer2, Eli Rosenbaum3, David Margel3, David Leonid Sarid4, Victoria Neiman3, Maya Gottfried1, Natalie Maimon1, Ilan Leibovitch1, Hadas Dresler1, Isaac Eliaz5. Questions:
1. Meir Medical Center, Kfar-Saba, Israel; 2. Rambam Health Care Campus, Haifa, Israel; 3. Davidoff Cancer Center, Petah Tikva, Israel; 4. Ichilov Medical Center, Tel Aviv, Israel; 5. Amitabha Medical Clinic and Healing Center, Santa Rosa, CA, USA


Thirty to fifty percent of prostate cancer (PC) patients (Pts) relapse biochemically
with rising prostate-specific antigen (PSA) after local treatment, and are classified as
non-castrate, biochemically relapsed (BRPC), non-metastatic (M0) disease.
Galectin-3 (Gal-3) is a carbohydrate-binding protein involved in cell-cell and cell-matrix
interactions in cancer progression (angiogenesis, metastases, immune evasion).

Pectasol-C® Modified Citrus Pectin (P-MCP), EcoNugenics, Inc., Santa Rosa, CA, USA,
acts as a competitive inhibitor of Gal-3. An earlier phase I pilot clinical trial (n=10)
showed a positive effect of P-MCP on prostate-specific antigen (PSA) dynamics in 70%
of patients with BRPC (M0) disease.


Primary: To evaluate rates of clinical and biochemical progression of patients with BRPC
(M0) treated P-MCP, given for six months.
Secondary: To evaluate toxicity, long-term benefit in responding patients, and correlations
between PSA dynamics and serum Gal-3 level.


Historically, an expected disease progression rate of 80% at 6 months in this patient population (natural history,
without therapy, based on an international database). Presently, 45 patients have now been enrolled. We report here
the first results of a pre-planned analysis after ≥ 50% of planned enrolled patients (n=35) completed 6 months of
therapy. Note: One patient withdrew his consent after 1 month.


PSA Dynamics
A stabilization or improvement (increase) of PSA doubling time (PSADT) in 79% (n=27) of patients.
A stabilization or decrease of PSA in 62%, (n=21) with negative bone & CT scans at 6 months,
and entered into the second 12 months treatment phase.
Increase in PSA velocity without change in scans in 12% (n=4) and with change in scans in 9% (n=3)
• No Pts had treatment related grade 3/4 toxicity.
• 18% (n=6) had grade 1 toxicity (bloating).
0% of Pts required interruption of P-MCP treatment due to adverse events.


The present analysis demonstrates benefits of P-MCP on progression of BRPC (M0) and exhibits 50% improvement over historical data. 62% of patients showed no progression during the study, as compared to continued PSA rise in consecutive tests prior to the study treatment. P-MCP is safe and has US-FDA GRAS status. A final report in the future will include full treatment data (n=60, 18 months). Correlative outcome analysis (serum Gal-3, cytokines, and immunological parameters) are in progress. We plan to conduct a randomized Phase 3 trial in order to support further these findings.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. 2018© ecoNugenics